WILMINGTON, Del.--(BUSINESS WIRE)--Results from the EROS real-world retrospective study showed that initiating fixed-dose triple-combination therapy BREZTRI ...

Breztri can cost $400 or more without insurance, but Medicare may cover inhaler drugs for COPD, including Breztri. That said, the specific coverage and costs vary based on your exact plan. Breztri ...

Breztri is an inhaled triple-combination therapy approved for chronic obstructive pulmonary disease (COPD) in adults in more than 80 countries worldwide, including the US, EU, China, and Japan. In ...

In a Breztri commercial that launched a year ago, a man using the AstraZeneca COPD inhaler was able to participate in hiking and other outdoor activities via an RV road trip. In this year’s spot, a ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca ...

AstraZeneca (NASDAQ:AZN) has initiated a Phase 3 study to evaluate the use of inhaled triple-combination therapy Breztri Aerosphere on severe cardiopulmonary outcomes, including death, in people with ...

After AstraZeneca’s fast-growing respiratory biologic Fasenra failed to move the needle in a COPD trial, hopes were directed to its three-in-one inhaler Breztri. But the potential challenger to ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s BREZTRI AEROSPHERE TM (budesonide/glycopyrrolate/formoterol fumarate) has been approved in the US for the ...

THARROS is the first-ever prospective trial to investigate the potential of an inhaled triple therapy to reduce cardiopulmonary events, a key driver of mortality, in COPD First patients dosed in ...

On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials ...

Approval based on Phase III ETHOS trial which showed a statistically significant reduction in the rate of exacerbations compared with dual-combination therapies WILMINGTON, Del.--(BUSINESS WIRE)-- ...